COLLABORATIVE ARRANGEMENTS (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Cost of Revenue, Total	$ 48,780,000	$ 12,692,000	$ 11,473,000
Research and Development Expense, Total	2,906,000	2,874,000	2,678,000
Riconpharma LLC [Member]
Cost of Revenue, Total	2,000,000
Research and Development Expense, Total	23,000	31,000	400,000
Sofgen Pharmaceuticals [Member] | April 2014 Sofgen Agreement [Member]
Research and Development Expense, Total		37,000	100,000
Sofgen Pharmaceuticals [Member] | August 2013 Sofgen Agreement [Member]
Cost of Revenue, Total	$ 600,000
Research and Development Expense, Total		$ 400	$ 200,000